Personal Digest: New obesity drug yields >20% weight loss in Phase 3
Welcome to Matters.com™ beta, where the world shows what matters. More information? Click here.
>20% weight loss — Retatrutide produced greater than 20% weight loss in a Phase 3 trial, signaling major potential to reduce obesity-driven GI disease burden.
 | CoffeeCold-brew recall, funky ferments, and shoppers nudged toward ethics Food Safety (delish.com) · Caffeine (13newsnow.com) · Fermentation (restaurantbusinessonline.com) |
 | ConstipationGut drug clears brain fog; dangerous DIY enemas trend lands people in ERs Prucalopride (medicaldaily.com) · Enema (newsable.asianetnews.com) |
 | PediatricsVaccine gaps, new IBD drug, and tiny hearts getting big grants Vaccination (idse.net) · Ulcerative Colitis (docwirenews.com) · Obesity (optometryadvisor.com) |
| GastroenterologyBig weight-loss drug, cirrhosis shift, and faster, less-painful scopes Obesity (medicaldialogues.in) · Liver Scarring (gastroenterologyadvisor.com) · Endoscopic (marketbusinessinsights.com) |
 | TelemedicineTelehealth fights for permanence as cyberthreats and new services rise Medicare (homehealthcarenews.com) · Cybersecurity (helpnetsecurity.com) · HIV (gayety.com) |